Children's Mercy Kansas City

SHARE @ Children's Mercy
Cancer Center Annual Reports

Oncology

2010

2009 Cancer Care Annual Report
Children's Mercy Hospital

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/
cancer_center_annual_reports
Part of the Oncology Commons, and the Pediatrics Commons

Recommended Citation
Children's Mercy Hospital, "2009 Cancer Care Annual Report" (2010). Cancer Center Annual Reports. 10.
https://scholarlyexchange.childrensmercy.org/cancer_center_annual_reports/10

This Book is brought to you for free and open access by the Oncology at SHARE @ Children's Mercy. It has been
accepted for inclusion in Cancer Center Annual Reports by an authorized administrator of SHARE @ Children's
Mercy. For more information, please contact library@cmh.edu.

2009
Cancer Care
Annual Report
Focus on ALL

Over 75 percent of children diagnosed with cancer
in 2010 will be cured and survive into adulthood.
That is encouraging news for a family struggling with
the news that their child is one of 12,000 children
diagnosed with cancer every year in the United
States. Cure rates today are dramatically higher
than they were just 20 years ago. But they are not
high enough. It is now more important than ever
to focus on research to continue to improve
outcomes in children with cancer. Fifty
years ago, a parent of a child with acute
lymphoblastic leukemia (ALL) was told that
this was an incurable disease. Today, 85
percent of children with ALL are cured.
This remarkable achievement is a result
of well-designed clinical research that is
conducted at multiple institutions across
the country and the world.
The Children’s Mercy
Hospitals and
Clinics’
Section of

Oncology is proud to be an important part of these
accomplishments. We are the sole regional site
for, and indeed one of the larger Childhood Cancer
Centers in the Children’s Oncology Group, the
National Cancer Institute’s cooperative organization
for childhood cancer research. Through this network,
nearly 100 clinical trials are available at Children’s
Mercy for children with cancer.
With 19 oncologists forming the
core of multidisciplinary and multispecialty teams, Children’s Mercy
is increasingly adding leadership to
these new research efforts through
our own investigator-led laboratory and
clinical research trials in areas such
as infant leukemia, brain tumor cancer
signaling pathways, T cell & relapsed ALL,
newly diagnosed, relapsed, and Down
syndrome associated AML,
experimental drug discovery,
pediatric drug formulation,
pharmaco-kinetics and
-dynamics, bone marrow
transplantation,
adoptive immune

and gene therapies, infectious complications,
supportive care, and survivor quality of life.
This year’s annual report for the Children’s Mercy
Cancer Center focuses on the most common type
of cancer seen in children, acute lymphoblastic
leukemia, commonly referred to as ALL. ALL can
affect children of all ages, but is most commonly
diagnosed in younger children. As with all
childhood cancer, the treatment of ALL requires
a multidisciplinary team with the knowledge and
experience necessary to handle all aspects of care.
At Children’s Mercy Hospitals and Clinics, we are
fortunate to have many dedicated people that are
focused on providing the best possible care for
children with cancer. This year’s annual report
highlights all of the people that are involved, and
emphasizes the role each plays in treating children
of all ages with ALL. We hope this report will serve
as an introduction to our team and the resources
we can provide to help children and families that are
diagnosed with cancer. We invite you to contact us
with any and all questions that you might have.
Our best wishes to you and the families of our
patients,

Alan S. Gamis, MD, MPH
Chief, Section of Oncology
Division of Hematology/Oncology &
Bone Marrow Transplantation
Professor of Pediatrics, UMKC School of Medicine

Dear Friends,
All of us at Children’s Mercy were so pleased and
proud when our oncology program again was awarded
the Outstanding Achievement Award by the American
College of Surgeons Commission on Cancer in
2009. This is the second time in a row that we have
received this prestigious three-year designation, which
is awarded to fewer than 20 percent of all adult or
pediatric cancer programs nationwide.
As you read through this annual report, you’ll
understand why the Children’s Mercy oncology
program continues to receive these types of honors.
Our physicians and nurses, our support staff and
our researchers are all exceptionally committed to
providing the finest state-of-the-art care for children
with cancer and support services for their families,
as well as cutting-edge research to help find new
treatments and cures for this disease.
We have one of the largest pediatric hematology and
oncology faculties anywhere in the nation, with more
than nine times as many pediatric oncologists as any
other program in our region and survival rates equal
to or better than the national averages. A number of
our physicians serve in national leadership roles in
organizations and research programs working with
childhood cancers.

This Cancer Care Annual Report focuses on Acute
Lymphoblastic Leukemia and the strides we have
made in providing care for children with this diagnosis.
It also provides you with a more complete overview
of the wide array of services, technology, staff and
quality that we are able to offer these children and
families at a truly challenging time in their lives.
I hope you will take a few minutes to read this annual
report and learn more about how Children’s Mercy is
caring for children with ALL and working as a national
leader in treating and researching cures for all types of
childhood cancers. I offer my sincere congratulations
and my deepest gratitude to everyone in our Division
of Hematology/Oncology for the extraordinary work
they do.
Sincerely,

Randall L. O’Donnell, PhD
President and Chief Executive Officer

The Division of Hematology-Oncology
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Growth in programs, services and personnel was
the theme for the Division of Hematology/Oncology
in 2008 and 2009. Dedication to excellence in
comprehensive care continues to be the main focus
of the staff working with patients who are experiencing
challenges with oncologic and hematologic diseases
and disorders.

the many details of patient care. From scheduling
appointments with other specialists, ensuring that
chemotherapy protocols are followed, dealing with
insurance issues and providing hands-on patient care
and education about diseases and treatment; the
Advanced Practice Nurses are essential members of
the team.

During 2008-2009, 16 physicians provided care
in both the inpatient and outpatient settings. The
Division continues to have over 1,000 inpatient
admissions and approximately 10,000 outpatient
visits annually. Research efforts are lead by the
physicians with their involvement in the Children’s
Oncology Group, Centers for Disease Control
and National Institutes of Health. In addition,
collaboration on research occurs locally,
regionally and nationally.

Nurses in both the inpatient and outpatient setting
provide safe and effective family-centered care. All
staff nurses receive extensive training in pediatric
hematology-oncology disorders, treatment modalities
and potential effects of treatment. Currently, more
than 40 staff nurses are Certified Pediatric Oncology
Nurses.

The team approach to comprehensive care
is the model that is practiced within the
division. Eighteen Advanced Practice Nurses
work alongside a physician to coordinate

Gerald Woods, MD
Division Chief, Hematology/Oncology
Section Chief, Hematology
Director, Sickle Cell Program
Professor of Pediatrics, UMKC School of Medicine

Because our patients require complex care that
involves many disciplines, the division operates closely
with other specialties such as Surgery, Endocrinology,
Neurology, Pathology and Radiology. Nutritionists and
pharmacists monitor each patient closely throughout
their course of treatment. Many additional team
members work behind the scenes to ensure that

the necessary support is in place for the direct
care providers, patients and their families. Support
services are essential to the care of these patients
who have many complex needs. Social workers assist
families with counseling, serve as an advocate for the
patient and family and provide expertise with resource
utilization. Psychology, Family Therapy, Child Life
Therapists and Music Therapists provide opportunities
for ongoing developmental growth and psychosocial
support for children that are experiencing serious
illness. Chaplaincy is available 24/7 to support the
spiritual needs of our patients, families and the
staff. Volunteers offer a listening ear and many other
comfort measures such as meals in the parent room
and special events during various times of the year.
Research and data managers who coordinate many
clinical trials, administrative assistants who maintain
communication both within the division and outside
the hospital, as well as schedulers who organize
appointments all serve as crucial members of the
team.

The Division added two new programs in 2009: the
Survive & Thrive Late Effects Clinic for childhood
cancer survivors and the Experimental Therapeutics in
Pediatric Cancer Program that is working to develop
and test new treatments for children with cancer.
We hope this report provides insight into the recent
efforts of the Division of Hematology/Oncology. We
especially hope that it demonstrates that the Division
offers many of the “million reasons” why Children’s
Mercy Hospitals and Clinics is one of the best places
to seek care for kids.
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A child diagnosed with leukemia is a jolt to any family,
but when the disease is treated and then returns, the
impact can even be a more powerful one. Madison’s
family found out that she had ALL when she was
5. Her mother remembers that it felt like it was the
end of the world. At the time, she knew nothing of
leukemia and didn’t even know “if it was fixable.” The
family credits the doctors and nurses who cared for
Madison with helping the family understand what their
treatment would be and what they could expect in the
months ahead.

Madison’s
a-Mazing
Marrow Match

After Madison completed her treatment, she went
about a year without any problems and was doing
great. That was when the one thing Madison’s mom
didn’t really expect to happen, happened. Madison’s
disease was back.
Again, Madison’s mom, Samantha, remembers how
Dr. Karen Lewing talked to her about the options for
treating her 9-year-old daughter. One of the options
was a hematopoietic stem cell transplant. Because
of the timing of Madison’s relapse, they would only
be able to do a transplant if Madison had a sibling
who matched her type of bone marrow. With
only a one in four chance of being a match, the
family anxiously awaited the results of her brother
Steven’s testing. When the news came that he
matched, the family knew that their next goal was
to keep Madison healthy until it was time to get
her transplant. She remembers, “That was a
struggle, but we made it.”
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For transplant, Madison had to switch treatment
teams from her oncologist, Dr. Lewing, to a doctor
that specializes in transplant. Samantha remembers

not being sure about that, but recalls her relief
that Dr. Doug Myers could not have been better.
“He explained everything in a way that we could
understand and both the kids really liked him.”
Madison entered the special bone marrow transplant
unit at Children’s Mercy several days before
her transplant. At that time she had received
chemotherapy that had made her disease go into
remission again. Once in the hospital, she would
receive very strong chemotherapy to get her body
ready for the new bone marrow. Without the strong
chemotherapy, her body would probably attack the
new bone marrow and not let it grow. The day of the
transplant, Steven went into surgery with a big smile
on his face. His mom remembers that he “wasn’t
one bit scared and this was his first time having done
anything like that.” Madison received her brother’s
bone marrow in a procedure very much like a blood
transfusion. After getting the cells, she had to stay in
the hospital until the new bone marrow grew enough
to make a brand new immune system that would now
protect her.
Madison is now more than two years past her
transplant and she is a happy, healthy girl. She
likes to draw and sing. She has a great sense of
humor and likes to tell jokes. Samantha is unable
to determine how Madison has or has not changed
because of what she has gone through. “It all started
when she was so young. What I do know is my family
is very thankful to Children’s Mercy Hospital. I don’t
think we’ve ever been treated so well!”
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Cancer Registry
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Award from the Commission on Cancer of the America
The Cancer Registry at Children’s Mercy Hospital
College of Surgeons. This award was only achieved
plays a vital role in the fight against cancer. Data
by 18 percent of the 432 cancer programs surveyed
is collected and maintained on all patients with
during 2009.
malignancies and certain benign tumors. This
confidential information will
During 2008 and 2009 the
assist health care providers
Cancer Registry added 316
and Researchers concerning
FAST FACTS - 2008 and 2009
patients to the database.
treatment methods,
• The median age of patients
Of these patients there
prevention, recurrence and
diagnosed during 2008 and 2009
were 259 malignancies,
survival.
was 10.5 years
14 benign or borderline
• The male/female ratio was 1:1.1
diseases of the central
The Cancer Registry operates
• Race distribution included 255
nervous system and 43
under the guidance of the
Caucasians and 33 African
reportable conditions. The
Cancer Care Committee and
Americans, with 28 patients
reportable conditions are
follows the data collection
designated as other race. Within
among a group of disease
requirements established by
the 255 Caucasian patients, 27
processes that the Cancer
the Commission on Cancer
patients were of the Spanish/
Care Committee has
of the American College of
Hispanic ethnicity.
agreed should be collected
Surgeons and the State of
• Geographically patients came from
because they are of local
Missouri. In October 2009
67 different counties. Fifty two
interest. Leukemia is the
the Commission on Cancer
percent of the patients were from
most frequent diagnosis
surveyed the Children’s Mercy
Missouri counties and 45 percent
during 2008 and 2009,
Hospital Cancer Program for
were from Kansas counties.
followed by tumors of the
the continued performance
Two additional states with
Central Nervous System.
of outstanding high quality
corresponding counties made up
The diseases of Lymphoma,
patient care. We were
three percent of the total patients.
Neuroblastoma, and
pleased to again receive
Rhabdomyosarcoma made
the Approval Award with a
up the remainder of the top
three-year commendation, in
five diagnoses during this two-year timeframe.
addition to the prestigious Outstanding Achievement

CANCER REGISTRY
FREQUENCY OF DIAGNOSIS BY YEAR
DIAGNOSIS BY YEAR			
2008
Central Nervous System		
35
Astrocytoma				
6
Glioma				
11
Ependymoma				
4
Medulloblastoma			
3
N.G. Germ Cell			
2
Pineoblastoma				
0
Desmoplastic Small Round Cell		
0
Choroid Plexus Carcinoma		
0
Benign / Borderline CNS		
9
Leukemia				44
ALL					33
AML					9
Other					2
Lymphoma				7
Non-Hodgkins				4
Hodgkins				3
Neuroblastoma			10
Hepatoblastoma			2
Osteosarcoma				3
Wilms Tumor				7
Rhabdomyosarcoma			4
Ewings Sarcoma (EFT)			
5
Other					14
Carcinoma				
5
Sarcomas				
2
Retinoblastoma			
2
Germ Cell Tumors			
3
Misc. Malignant Conditions		
2
		
Misc. Reportable Conditions		
20
		
TOTAL BY PER YEAR			
151

2009
28
9
4
2
5
0
1
1
1
5
48
35
11
2
13
6
7
6
3
4
7
11
5
17
4
4
3
1
5
23
165
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Quinton knew that the summer of 2010 was going to
be one of new experiences. He had just graduated
from Leavenworth High School and was ready for a
new chapter of his life to begin. Quinton spent his
senior year in the prestigious position of Battalion
Chaplain of his school’s ROTC program. He was
awarded this position after having gone through
a rigorous application process involving his peers
and instructors. In the end, Quinton was chosen
for the role because his commanders knew that he
would be a moral and spiritual leader that the other
cadets would turn to for advice and support. Quinton
excelled in the position. Because of his exemplary
high school performance, he was now preparing for a
four-year stay at his dream school, Kansas State, his
tuition being paid by a full Army ROTC scholarship and
acceptance into the Smith Scholarship House.
Soon after graduation, Quinton had gone with friends
on a service trip to Colorado Springs where they
worked to help military families who had loved ones
out of the country. During the times when he and his
buddies were chopping and hauling wood and joking
about their extraordinary strength, Quinton was also
feeling run-down and not himself. He was used to
always being full of energy – he ran cross-country
track, loved other sports and was always on the go.
Back home in Leavenworth, Quinton’s parents
took him to see a doctor who thought he had
mononucleosis. When he didn’t get better, more
tests were done and he was sent to Children’s
Mercy Hospital where he was diagnosed with Acute
Lymphoblastic Leukemia. Quinton spent close to two
weeks in a hospital bed during June. During that time
his body hurt, his head ached, and he was so tired

that he had to be coaxed to get out of bed and to
use his muscles. He got chemotherapy; he got blood
transfusions; and he thought a lot about how all of
this would impact his plans for the future.
Now, several months after hearing the news, Quinton
has accepted his diagnosis. His doctor, nurse
practitioner and social worker have spent time with
Quinton and his family to make sure they understand
what treatment will be like and what they can expect
over the next three and a half years that his treatment
will last. Because most of the treatment can be given
as an outpatient, Quinton now spends much of his
time in the Hematology/Oncology Clinic. Not going
into the hospital is great for him, but
the clinic days are
long when they
involve having
blood work
done, waiting
for the results,
and getting
chemotherapy that
can take a long
time to infuse into
the catheter that he
has implanted in his
chest.
When asked what
it is like to come to
Children’s Mercy as one
of the older patients,
Quinton says it makes
him glad. He says that
the people at Children’s

Mercy have a gentle touch that he appreciates. He
also says that he has learned more about himself
during this and sees what he can adjust to and get
through. Quinton says that he has many people
“praying their eyeballs out for him,” and he thinks that
one day he will be able to use his own experience to
help other kids with cancer. When asked where he
sees himself in 10 years, he thinks that maybe he will
be an officer in the army, but he expects that he will
be in a role where he can teach and he can listen.
He says that he knows he “can’t make everything all
better, but I can be a person who will listen and hear.”

Quinton’s
Quest for
a Cure
Quinton will miss going to Kansas
State in the fall. He may lose
his scholarship due to health
requirements of his reward.
Talking to Quinton, however,
you would not detect anger,
resentment or any other
negative emotion that would
almost seem natural. What
you see is a strong young man
who lives every day with the
faith that he can make it a good one.
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Acute lymphoblastic leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is the most
commonly diagnosed cancer in children. Every year,
there are about 2,400 children diagnosed with ALL in
the United States. Approximately one quarter of the
children seen at Children’s Mercy Hospital and Clinics
for cancer treatment have ALL.
Leukemia is a cancer of white blood cells. ALL begins
within the bone marrow in a specific type of white
blood cell called a lymphocyte. Normal lymphocytes
within the body help to fight infections and we cannot
survive without them. In ALL, the growth of certain
lymphocytes becomes abnormal, and they begin to
grow and divide very quickly. Because these cells
are growing so rapidly, the production of other cells
that normally grow in the bone marrow such as red
blood cells, platelets, and healthy white blood cells
is diminished. This results in many of the symptoms
that are seen at diagnosis. By the time ALL is
diagnosed, there are over a trillion leukemia cells in
the circulation.
ALL can present with a variety of symptoms and
is often initially misdiagnosed. Symptoms seen in
patients with ALL include fever, fatigue, anemia,
bruising, bleeding, enlarged lymph nodes, an enlarged
liver or spleen, or bone pain. Diagnosis is often made
after a complete blood count (CBC) is ordered and
abnormal white blood cells called lymphoblasts are
seen.

Little is known about the causes of ALL in children and
the vast majority of cases occur in healthy children.
ALL is seen more commonly in males, and the most
likely age at diagnosis is between 2 and 5 years. ALL
is more common in white children when compared to
black children. It is seen more frequently in children
of families with higher socioeconomic status, for
reasons that are not well understood. There are
certain genetic syndromes that are predisposed to
developing ALL, the most common of which is Down
syndrome. Other syndromes that can predispose to
the development of ALL include: Bloom syndrome,
neurofibromatosis, Klinefelter syndrome, and ataxiatelangiectasia.
The improvement in survival for children with ALL over
the last 40 years is one of the true success stories
of modern medicine. As recently as the 1960’s,
the diagnosis of leukemia for a child was considered
terminal. With current therapies, a child diagnosed
with ALL today will have above an 80 percent chance
of cure.
ALL is treated with chemotherapy, and treatment
can last as long as three and a half years. One of
the most remarkable aspects of the improvements
in the outcome of patients with ALL is that they
have occurred without the benefit of new medicines,
but with improved knowledge and understanding of
medicines that have been around for a long period of
time.

in the CNS, but the long-term effects of this treatment
were substantial. For young children that are still
developing, radiation directed at the CNS could cause
learning disabilities, growth defects, and abnormalities
of hormone production. Over the past 20 years,
preventive treatment of CNS relapses has shifted
from radiation to chemotherapy administered directly
into the cerebrospinal fluid. Using chemotherapy
has proven to be just as effective at preventing CNS
relapses with a lower incidence of severe side effects,
and is now used
ALL IN CMH PATIENTS
for all but the
OVERALL FIVE YEAR SURVIVAL IN YEAR BLOCKS 1990-2004
highest risk
2000-2004
patients.
n=112

The earliest attempts at the treatment of ALL included
one chemotherapy drug. This treatment would result
in some remissions, but all patients would eventually
relapse. This led to the use of multiple chemotherapy
drugs in combination, and improvements in the
number of patients that respond and even long term
cures were seen. Now, almost all patients are able
to achieve remission after one month of induction
treatment that includes three to four chemotherapy
medications.

100%
90%

OS=92.5%
80%

1990-2004
N=299
OS=85.4%

Other
improvements
60%
1990-1994
Survivors
in the delivery of
N=83
OS=81.1%
50%
chemotherapy
40%
include the
30%
use of an
20%
additional phase
10%
of intensified
treatment
0%
0
50
100
150
200
250
300
and the use
Elapsed Time - weeks
of low dose
ALL- 1990-1994
ALL- 1990-2004
ALL- 1995-1999
ALL- 2000-2004
chemotherapy
for an extended
period of time, referred to as maintenance therapy.
One of the earliest lessons learned when more
Patients that are receiving maintenance therapy take
and more children were being cured of ALL is that
medicine at home every day, and are seen in clinic
leukemia cells that were present in the cerebrospinal
on a monthly basis for laboratory monitoring and an
fluid were protected against the effects of
intravenous dose of chemotherapy. Patients in this
chemotherapy, and many relapses occurred in the
part of their treatment are just like other children;
central nervous system (CNS). CNS directed therapy
they regrow their hair and attend school daily. This
initially included treatment with radiation directed at
maintenance phase of treatment lasts for one and a
the brain and spinal cord. This led to fewer relapses
70%

1995-1999
N=104
OS=81.5%

half years for girls and two and a half years for boys.
Other improvements in the treatment of ALL in
children have come from a better understanding of
the disease and the knowledge of specific risk factors
that are present at the time of diagnosis. Although
ALL cannot be staged like other kinds of cancer, there
is a lot of information that is used to classify patients
into risk groups, with higher risk patients receiving
more aggressive therapy to prevent relapse.
Age is an important risk factor in ALL. Children
diagnosed with ALL have much better chance of
survival than adults with the same diagnosis. Along
those lines, younger children have an improved
chance of cure compared to older ones. The
exception to this rule is that infants less than one
year of age with ALL typically have a specific genetic
abnormality in their leukemia cells that makes them
high risk. Because of this, they are treated more
aggressively. Currently in the United States, patients
older than 10 years are considered to be high risk.
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target this mutation, dramatic improvements have
been made in the survival of these children. These
‘targeted’ treatments are an important focus of new
research in oncology. The success achieved in ALL
with the Philadelphia chromosome utilizing targeted
therapeutics serves as a model for integrating new
advances in our understanding of the biology of ALL
into improved outcomes for patients.

ALL Overall Five Year Survival by AGE
1990-1999

100%
1-10 yrs
n= 138
OS= 85.4%

90%
80%

>10 yrs
n=40
OS= 65.5%

70%
60%
Survivors

<1 yr
n= 9
OS=53.3%

50%

The remarkable improvement in cure rates for children
with ALL is looked at as one of the most impressive
achievements of modern medicine. Through clinical
research trials that include a great number of children,
improvements continue to be made. Children’s Mercy
Hospital is a member of the Children’s Oncology
Group, an international collaboration focused
on conducting clinical trails in childhood cancer.
Currently, there are multiple open clinical trials at

40%
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20%
10%
0%
0
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300

Elapsed Time - weeks

White blood cell count at diagnosis is also a risk
factor. Since the majority of white blood cells in
patients with ALL are leukemia cells, this number
represents the amount of leukemia present within the
patient. A white blood count of greater than 50,000
cells per microliter of blood qualifies as high risk.

ALL Overall Survival by Age
2000-2009
100%
1-10 yrs
n=217
OS=94.6%

90%
80%
70%

Whenever a patient is diagnosed with ALL, the DNA
of the leukemia cells is analyzed. There are specific
genetic mutations that when detected can tell us
whether the leukemia cells may be more or less
susceptible to treatment. These genetic risk factors
are taken into account when planning treatment. One
particular genetic abnormality called the Philadelphia
chromosome is seen in a small percentage of
children with ALL, but heralds a much more guarded
prognosis. By integrating newer treatments that

>10yrs
n= 49
OS-76.3%

60%
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ACUTE LYMPHOCYTIC LEUKEMIA / AGE 0-19
5-YEAR SURVIVAL COMPARISON RATE
SEER 5-YEAR RELATIVE SURVIVAL RATES (PERCENT)*
CMH 5-YEAR KAPLAN-MEIER ADJUSTED SURVIVAL RATES (PERCENT) **

CMH
SEER

1990-1992
1993-1995
1996-1998
1999-2006
1990-1992		1993-1995		1996-1998		1999-2006
71.9 			79.8			76.3			91.1(n= 41) 		(n=66) 		(n=55)			(n=199)
80.0			81.4			84.2			85.9

SEER follow-up of patients into 2007
For Children’s Mercy patients we calculated 5-year survival for the time periods noted. For this
group of patients, the overall median length of follow-up was 376 weeks.
* Table 28.8 SEER Cancer Statistics Review 1975-2007 (National Cancer Institute)
** Cancer Registry Management: Principles and Practice- pg 431 comparison of Relative
And Kaplan-Meier Adjusted Survival Modules

Children’s Mercy Hospital for ALL, both for patients
when they are first diagnosed and for when relapses
occur.
The future for ALL treatment in children is bright.
Improvements continue to be made in cure rates,
and our goal of curing 100 percent of children is
within reach. Newer technologies are being utilized
to learn much more about the genetics of ALL, and

how differences in the genetics of individual patients
can dictate how they respond to chemotherapy. By
integrating this new information into treatments,
their effectiveness can be enhanced while reducing
the incidence of short and long term side effects of
chemotherapy.
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Carly’s
Courage

Carly Bachman was 3 years old when she was
diagnosed with ALL. When asked about her memories
of that time, she says “I don’t remember much, but I
do remember coming [to the hospital] in the middle
of the night and bringing all of my beanie babies.”
Her mom remembers the event very differently. What
they were told that night would drastically change the
family’s life.
Looking at the healthy 17 year old today, you can

understand why her family calls her the “Miracle
Child.” Carly is an active premier soccer player who
looks forward to continuing her soccer playing into
college. In her words, soccer brings Carly “joy and
happiness.” When she chooses a career, she wants
to work with kids. Her mom, Rachel, agrees that Carly
will be great at this because she loves to play with
kids and the kids love her.
Carly’s memories of her diagnosis and treatment are
not as clear as her mom’s. She does remember
that she did not like the shots she had to get in her
legs several times a week. She was good at keeping
track of which leg had most recently been used for
the shot so the nurses could use the other one.
She remembers her dad coming up with the name
“Buddy” for her port-a-cath. Buddy allowed her to
get her chemotherapy without a new IV being put in
each time. Carly remembers the days in the hospital
with some fondness. Being in the hospital meant
lots of visitors bringing lots of goodies! A goody
that she does not remember fondly
is strawberries. After not eating
all day because she was having a
procedure, she eagerly gobbled up
the big bowl of strawberries one of
her nurses brought in for her. Carly
laughs, remembering getting sick
and not liking strawberries any more
after that. She also doesn’t have
the same love of French fries. She
ate lots of them when she was at her
most vulnerable to infection. During
those times, when she couldn’t
go out into public, her mom would
bundle her into the car for a drive

around the neighborhood and finish with a trip through
the drive-through.
Carly does not talk much about her fight and victory
over leukemia. Carly’s nurse, Cathy Burks, says that
is just the way Carly is. She will not draw attention
to herself. She has some friends who know what she
went through as a child, but not all do. When they
find out, they are surprised, but not at all surprised
that Carly beat her cancer. After all, the word that she
says that they would use to describe her is “strong.”
Nowadays, Carly is among the growing number of
childhood cancer survivors. Sitting and talking with
Carly, her mom, and Nurse Practitioner, Cathy Burks,
it feels more like friends catching up after an absence
than a clinic appointment. Last year for the first
time, Carly attended the new “Survive and Thrive
Clinic” rather than her usual yearly appointment
with her treating doctor, Gerald Woods. During her
appointment at the Survive and Thrive clinic, Carly
had her usual physical exam, but special attention
was paid to those areas of concern for people who
received the type of therapy she did. She also got
to spend time with other specialists like an oncology
social worker and registered dietician. When she left
the clinic, Carly received lots of information that would
help her make health decisions as she aged out of the
Children’s Mercy population.
Almost 15 years have passed since Carly and her
family made the trip to Children’s Mercy that would
change the way each of them looks at life. She is
definitely strong, but she is also a friendly, humble,
charming teenager – who also happens to have once
had childhood ALL.
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Cathy Burks, RN, PCNS, CPON

Advanced Practice Nurse working with Gerald Woods, MD
Cathy Burks has worked in pediatric Hematology-Oncology for 30 years. Much has
happened during those years, but Cathy especially marvels at the improvement in
survival rates. Cathy notes that, “It is exciting that our treatment protocols have been
able to respond to the cure rate being so high that now we look at the long term
effects and try to amend our treatment to lessen those! In the 1970’s we were just
trying to buy time. Worrying about late effects was pointless.”
Cathy is also grateful for the changes in techniques for giving drugs. Central lines for
venous access help to avoid the often numerous pokes to find a vein at each clinic
visit. There are also better drugs for nausea and pain, as well as better antibiotics.
Our ability to deal with side effects and toxicities has improved dramatically. The
more kid-friendly and appealing space is also a great improvement. She finds that
kids now stroll into clinic knowing they will have fun if at all possible.
Cathy reflects on her career and states how very aware she is of how fortunate she
and her husband are. Raising their daughters without the challenges of chronic
or life-threatening illnesses is something she cannot take for granted when she
knows so many families who have had such different journeys.
Cathy says she is in awe of how well the child and family handle the obstacles
and challenges they face on a daily basis. She admires the strength of a
family called on to deal with cancer and how they often find a way to be closer,
stronger, and more appreciative of things in life the rest of us may well take for
granted.
Cathy credits the special people in the Hematology-Oncology Division for
creating special connections with the families served. “We have the honor to
help the families that come to us. Our staff pulls together to help a child that
we are honored to know.”

Diagnostic Treatment and Support Services
Pathology
When a child comes to Children’s Mercy Hospital
with a suspected diagnosis of ALL, the diagnosis is
confirmed with routine and special pathology studies
on peripheral blood, bone marrow, and/or spinal
fluid. The number and type of leukemia blast cells is
determined by the pathologist who looks at the cells
through a microscope. In addition, flow cytometry
tests are done that employ tagged antibodies to
confirm specific lymphocyte lineage (either T or B
lymphocyte lineage), as well as establish the stage
of T or B cell maturation (i.e. early, common or
middle, and late or mature). Stages of maturation
carry prognostic significance. Common pre-B stage
leukemia is generally favorable, especially compared
to the B-cell ALL that lacks the common childhood
ALL marker, CD10. Similarly, T-cell ALL that express
the common thymocyte marker, CD1a, or coexpress
CD4 and CD8, is prognostically more favorable than TALL that does not express these cell surface markers.
Bone marrow is collected at points during treatment
to allow the pathologist to determine how the child
has responded to therapy.
The Pathology Department of Children’s Mercy
Hospital also employs flow cytometry testing to
detect residual ALL in bone marrow when the blast
level falls below conventional morphologic means of
detection (minimal residual disease [MRD] testing).
Normal bone marrow contains about 1-3 percent
blasts that ultimately give rise to, and mature into
normal peripheral blood cells. On the basis of results

from a comprehensive panel of markers done on the
initial leukemia cells prior to treatment, a special set
of informative markers are selected for each patient
that distinguish the leukemic cells from normal
progenitors. These markers are again tested for on
post-treatment bone marrow samples. MRD is a
very useful tool for monitoring treatment response
when patients are in, what is conventionally defined
as, “remission” (i.e. less than 5 percent blasts in the
marrow). MRD is also useful for both predicting a
potential for a higher risk of relapse (if there are more
than 0.01 percent MRD positive cells at the end of
induction therapy), and for detecting relapse before
the disease reaches conventionally high levels.

Predominence of
lymphoblasts and few
normal lymphocytes

Blasts that have
dual expression
of CD19 (B
cell marker)
and CD10
(Childhood acute
lymphoblastic
leukemia
antigen)

Cytogenetics
Current treatment strategies adjust therapy of
leukemia patients according to the genetic subtype of
the individual tumor. Cytogenetic analysis plays a vital
role in defining this genetic subtype of leukemia cells.
Cells from each newly diagnosed leukemia patient are
studied in order to optimize therapy using the least
toxic, most effective therapeutic regimen.
A blood or bone marrow sample is sent to the
Cytogenetics Laboratory at diagnosis. The leukemia
cells from the sample are cultured and harvested
during the metaphase portion of the cell division
cycle (a seven minute window). The harvested cells
are applied to glass slides and the chromosomes are
stained to show the band pattern. This allows each
chromosome to be identified and analyzed by skilled
technologists.
Metaphase chromosomes are analyzed for any
and all genetic defects, including the number of
chromosomes (normal is 46) and any structural
defect. Structural rearrangement of chromosomes
frequently identifies cancer-specific genes. Research
has shown that some of these genes can be targeted
by mutation specific therapies. An example is the t
(9;22) that results in rearrangement of the ABL1 gene
on chromosome 9 with the BCR gene on chromosome
22. This rearrangement changes a normal tyrosine
kinase gene into one which drives cell proliferation
and leukemogenesis. Tyrosine kinase inhibitors have
been identified to target the abnormal BCR/ABL1
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fusion product. Targeted therapies are less toxic
than conventional cell cycle chemotherapy and more
effective since they target the specific genetic defect.
The Cytogenetics Laboratory submits the cytogenetic
data to the Children’s Oncology Group (COG)
Cytogenetics committee when a patient is enrolled on
a COG study. This information is used to determine
which arm of a COG therapy protocol is most
appropriate for each child. COG collects this data
from many institutions that enroll their patients on
study. The collected data is analyzed at the end of
the study to correlate between genetics and patient
outcomes. This information provides valuable
guidance on the most effective therapy for specific
genetic abnormalities.
In addition to the conventional chromosome analysis,
the Cytogenetics Lab performs FISH (fluorescence in
situ hybridization) analysis to detect submicroscopic
chromosome abnormalities and to confirm the
molecular rearrangements caused by chromosome
translocations. All information gathered from these
methods is utilized in determining the most effective
therapy for each patient.
Follow-up cytogenetic or FISH analyses are done
to determine the presence or absence of residual
disease after treatment. Residual disease has
prognostic significance. If there is a relapse of
disease, conventional chromosome analysis will
determine if there are changes in the genetics of the
leukemia (i.e. clonal evolution).
The goal of the Cytogenetics Lab is to determine,
with the greatest accuracy, what the genetics are for

each child’s leukemia so the child can receive optimal
therapy and the best chance for long- term survival.
Pharmacy
Over last decade, chemotherapy for ALL has become
more specialized. Patient treatment - both the
number and dose intensity of chemotherapy agents
– is based on each patient’s risk for relapse. Many
new drugs have also been incorporated into the
treatment of ALL. These drugs are given based on
the type of leukemia or specific genetic abnormalities.
The tyrosine kinase inhibitors such as imatinib and
dasatinib (both oral agents) are now included in
the treatment regimens for patients with t(9;22)
translocation. Other new agents that have been used
in the treatment of ALL include nelarabine for T-cell
ALL and clofarabine, the first drug within a decade to
be FDA-approved specifically for the treatment of a
pediatric cancer.
The Pharmacy Department is integral to the
complete care of oncology patients. The Children’s
Mercy Pharmacy staff and facilities have evolved
over the past decade with a goal of providing the
best pharmaceutical care possible for all patients,
including those with cancer. The distinct teams within
this department include Inpatient/Clinic Operations,
Clinical Specialist Pharmacists, Investigational Drug
Service, Home Care and Outpatient Operations.
Within the Hematology/Oncology Division, three
clinical pharmacy specialists work with patient
families and assist the primary team in optimizing
patient medications based on drug interactions,
disease states, and organ function. In addition
to our pharmacy specialists, three pharmacists
and a technician are dedicated to the review of

chemotherapy orders and safe production and
distribution of chemotherapy to all patients within
the Children’s Mercy system. Our investigational
drug service works with over 100 open drug trials for
our patients, including many phase II oncology drug
studies. Our outpatient pharmacy is able to compound
many prescriptions that are not commercially
available.
Our Hem/Onc pharmacists are dedicated to
providing education to pharmacy students through
clinical rotations and lectures at our local school of
pharmacy. In addition, our Pharmacy Department
has two nationally accredited post-graduate residency
programs. In 2008 we became only the second
program in the nation for post-graduate residency
training of pediatric hematology/oncology pharmacists.
This residency program provides pharmacists with
focused and intensive training in the care of pediatric
patients with cancers.
Inpatient Nursing
Nurses at the bedside have seen many changes and
growth in the treatment of ALL in the last decade.
With the use of Gleevac for High Risk ALL, nurses
have witnessed more positive outcomes for their
patients. Relapsed ALL patients now have more
options for treatment, including the possibility of a
bone marrow transplant. With the improvements in
treatment, Standard Risk ALL patients are rarely seen
inpatient for treatment or side effects. Bedside nurses
are provided more resources and education to assist
families at the time of diagnosis. This has allowed us
to prepare our families to care for their children and
understand the treatment.

While the physicians and residents are responsible for
all aspects of diagnosis, nursing input is welcome and
valued. It is usually the inpatient nurse’s responsibility
to coordinate care between the multi-disciplinary care
teams. Inpatient nurses are the front line of daily
care, alerting the care team to changes in patient
status. Patients and their families rely on the nursing
staff for new diagnosis education as well as assisting
the social workers with psychosocial care during a
stressful time of life.
Clinic
The Children’s Mercy Hospitals and Clinics
Hematology/Oncology Clinic nursing team are the first
line providers of patient care in the outpatient setting.
Every patient has a primary care team that consists
of an attending physician, advanced practice nurse,
and social worker. Nursing follows this model. Having
a primary nurse during a lengthy treatment allows for
consistency in care and optimal patient and family
experiences. Each nurse works with a set of patients
and families with whom they will develop professional
relationships that foster understanding and trust and
a reduction in overall anxiety. Our nursing team is
able to provide the supportive care, education and
anticipatory guidance appropriate for each individual
patient and family member. This is based on their
knowledge and understanding of each patient’s
diagnosis, treatment plan, educational needs, and
family dynamic.
As the first health care providers to access
patients in the Hematology/Oncology Clinic,
nurses are responsible for medication and allergy
histories, obtaining a history of symptoms, and
for providing nursing interventions, such as

medication administration. At Children’s Mercy, the
Hematology/Oncology nurse is required to be certified
in the following: Chemotherapy and Biotherapy
administration, Basic Life Support, Pediatric Advanced
Life Support, central line care, and sedation. In
addition, nurses are required to take and pass the
General Anesthesia Registered Nurse course provided
by the hospital and a Bone Marrow Transplant course
provided by the Division of Hematology/Oncology. In
addition to Children’s Mercy requirements, many
of our nursing staff members voluntarily test to
become certified in pediatric oncology (Certified
Pediatric Oncology Nurse), demonstrating an expert
knowledge base in this specialty. Because of this,
nurses are equipped to provide the same treatment
that would be otherwise be provided in an inpatient
setting. Treatment provided includes: chemotherapy,
high risk biotherapies and monoclonal antibodies,
stem cell infusions, administration of blood products,
and sedation for procedures. Nursing also provides
supportive care for the Hematology/Oncology patients
who require anesthesia for procedures, but are not
candidates for sedation. candidates and require
anesthesia for procedures. Nurses in the clinic must
also be prepared to care for children that present
with oncologic emergencies, such as anaphylaxis
and sepsis. This means knowing what resources are
available and accessing them appropriately.
FACT Team
Although there have been many advancements in
treatment for children with ALL, caring for a child
diagnosed with ALL remains a daunting road for
parents, siblings, family members and friends. The
Hematology/Oncology Family Care Team (FaCT)
recognizes that treatment is not merely a series of

chemotherapy, clinic appointments and inpatient
admissions. It is a process where the most important
outcome is that the patient and family are able to
redefine their ‘new normal’ during treatment and
after treatment ends. For many patients and families
experiencing leukemia, life will never again be the
same. They require continued adjustment with each
new developmental stage of their life.
The FaCT team consists of social workers, child life
specialists, music therapists, a family therapist,
a psychologist, a chaplain and a hospital -based
school teacher. Each of these highly specialized staff
members is equipped to support families through
each step of the process, including diagnosis, active
treatment, end of treatment, and late effects. The
overarching goal of the FaCT team is to assist each
patient and family member by providing support and
guidance on an individual basis.
Since ALL treatment lasts two to three years, the
impact on children and families is large. Members
of the FaCT team are available to provide support
to the patient, families and school staff in order for
the patient to stay connected with their peers during
treatment. Team members can meet with siblings and
classmates to provide education about the diagnosis
and treatment and facilitate discussion of how they
can support the patient in their treatment process.
As part of an ongoing relationship with each patient
and family, the family care team considers it a
privilege to accompany patients and families on their
journey and bear witness to their determination,
courage and resilience.
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Nutrition
A child’s appetite and weight change while undergoing
therapy for ALL is similar to riding a roller coaster.
Families are frequently frustrated when the thing that
their child was craving is pushed aside after only a
couple bites.

during most cancer treatments. Increased fruit and
vegetable intake throughout ALL therapy is associated
with fewer hospitalizations for blood stream infections
and lessened chemotherapy-related toxicities. This
helps children finish their lengthy course of therapy on
time.

Nutrition therapy for a child with ALL centers around
assessing the child’s usual diet and the family’s health
habits. Nutritionists provide anticipatory guidance
related to taste changes, steroid-induced weight gain,
and increased vitamin and mineral requirements while
on chemotherapy.

Another major nutritional concern is decreased
bone mineral density and risk of osteopenia or
osteoporosis. Children undergoing treatment with
steroids have increased calcium and vitamin D needs
in order to maintain normal growth and development.
Nutritionists evaluate diets and the child’s current
intake levels of these important nutrients. Education
is provided to families with tips for dietary changes or
appropriate supplements as indicated.

The consequence of prolonged inadequate intake
is nutrient deficiencies that can lead to increased
chemo toxicity. Prolonged inactivity decreases energy
expenditure which can lead to further decreased
appetite as well as later risk for obesity. At other times
children struggle with excessive cravings and eating
caused by the steroid component of therapy, which
leads to a concerning pattern of obesity. Children with
ALL who are not following age-appropriate growth
rates, based on their growth chart, are referred for
nutrition assessment and recommendations.
Changes in nutrition therapy for children with ALL
over the past decade relate to vitamin/mineral needs
and obesity prevention. Nutrients found in fruits and
vegetables, called phytochemicals, are now strongly
encouraged at age-appropriate amounts (5-9 servings
per day) throughout ALL therapy, unlike previous
recommendations for neutropenic diets (only frozen or
canned fruits & veggies). Safe food handling, including
appropriate washing of fresh fruits and vegetables,
has replaced neutropenic diet recommendations

Nutrition education for children with ALL also deals
with the increased incidence of obesity in adult
survivors of childhood leukemias. This is especially
seen in those who required CNS radiation and/or
stem cell transplant. Screening for obesity risk factors
throughout therapy and annually after completion of
therapy is essential to identifying children and young
adults who would benefit from additional nutrition
assessment and education.
Stem Cell Transplant
The Stem Cell Transplant team is comprised of
specially trained pediatric hematologist/oncologists,
advanced practice nurses, physician assistants,
pharmacists, transplant coordinators, and research
staff. Each team member plays a part in taking
care of children who are referred to the team for a
transplant. Indications for a transplant following a
diagnosis of leukemia are relapse and disease that

does not respond to chemotherapy. Because each
child is unique, a full consultation is done with the
family members before it is decided how or if to move
forward with transplant.
Children’s Mercy offers families the opportunity to
have a gold standard transplant within the specially
designed transplant unit of the inpatient floor. Care
is provided by trained caregivers who understand the
intricacies of caring for these patients.
Research
Progress in the treatment of ALL is one of the leading
success stories in all of cancer research. The
dramatic breakthroughs, for the most part, have
come through clinical trials. Most of the clinical trials
offered to patients with ALL in the United States come
from a cooperative effort with the Children’s Oncology
Group (COG), an association of institutions dedicated
to research in pediatric oncology. Lessons learned
from the treatment of childhood ALL have been
applied to other less curable cancers, even those that
strike adults.
COG offers clinical trials to study every gamut of ALL.
Current areas of research include:
•
Epidemiology and Biology
•
Treatment protocols
•
The use of investigational new drugs
•
Relapse/Refractory Disease
•
Late effects and long-term follow up
Biology/Laboratory Research
Over the past 10-15 years, researchers have made
progress in the basic scientific understanding of ALL.
A single cell in the body develops some mistakes

in the genes crucial for controlling cell growth and
development. Those mistakes (called mutations)
make the cancer multiply. By enrolling patients on
biology studies, we are learning why these mistakes
occur and how knowledge of these abnormalities
can be used to improve treatment for children and
adolescents with ALL.
Treatment Protocols
Clinical trials for the treatment of ALL are focusing
on risk-adapted therapy. This helps low-risk patients
(patients predicted to have a very low risk of relapse)
avoid unnecessary treatment and side effects, while
giving higher-risk patients stronger treatment to
improve their chance of being cured. Therapy is
tailored to the individual patient based on a series of
clinical (age, gender) and biological features (white
blood cell count, chromosome content of blasts) at
diagnosis as well as an assessment of how quickly the
leukemia responds to treatment.
Treatment of Relapsed and Refractory ALL
Despite the progress made in treating children with

ALL, children still relapse.
Since it is more difficult
to cure a child who has
relapsed, better treatments
are being sought for these
patients. Laboratory
studies are helping us to
understand why some
patients with ALL relapse,
but others do not. New
drugs are being rapidly
integrated into conventional
chemotherapy protocols to
improve outcome. Clinical
trials have been designed to evaluate new drugs in
the context of more conventional therapy to speed the
development of promising new agents. In addition,
COG is aiming to improve outcomes after stem cell
transplant by decreasing the burden of leukemia
prior to transplant and piloting the use of drugs that
simultaneously combat the leukemia and prevent graft
vs. host disease.
Long Term Follow up and Late Effects
Ongoing clinical research is determining which
patients are at greatest risk for known side effects
and intervention trials are now planned to decrease
the psychological burden on patients and families, to
prevent neuro-psychological deficits, and to decrease
problems with bone and joint development and
muscle strength and flexibility.
Survive & Thrive
Survival is now a reality for almost 80 percent of
children diagnosed with cancer. In the U.S today
there are over 270,000 childhood cancer survivors.

While surviving is a major accomplishment in itself,
many of these children will have the challenge of
some kind of health problem related to their treatment
for cancer, even years after that treatment has ended.
These “late effects” of childhood cancer can
include heart and lung dysfunction, growth issues,
psychological and educational concerns, as well as
the possibility of a second cancer. The Division of
Hematology-Oncology created the Survive & Thrive
Late Effects program to provide comprehensive
physical and psychosocial assessment. The program
provides a treatment summary for each patient
and educates them on what late effects they may
be at risk for, what type of health care follow-up is
necessary and how to make healthy lifestyle choices.
The Survive & Thrive Clinic is staffed by a medical
director, nurse coordinator, clinical social worker
and registered dietician. We also work closely with
a radiation oncologist and endocrinology physicians.
Other specialty services are consulted as needed.
An additional goal of the clinic is to assist patients
in making the transition from pediatric care to adult
health care, ensuring that they will continue to get the
long term follow up they need.
The Survive & Thrive Late Effects program is important
because even though these kids have survived their
cancer diagnosis and treatment, they can still face
incredible challenges in their lives with many chronic
and debilitating health issues. Our goal is to identify
these issues and provide them with the resources they
need to live the healthiest and most productive life
possible.
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